Life Sciences
Accounting and Financial Reporting Update — Interpretive Guidance on Consolidation
March 2018
Consolidation

Introduction

Life sciences entities enter into a variety of arrangements with other parties to facilitate the research, development, or sale of their IP or products. Because life sciences entities may absorb the risks and rewards of other parties through interests other than those based on traditional voting equity, they must carefully analyze their arrangements with those parties to determine whether to consolidate them. The dual consolidation model, which comprises the VIE model and the voting interest entity model, is designed to ensure that the reporting entity that consolidates another legal entity has (1) the obligation to absorb losses of, or the right to receive benefits from, the legal entity that could potentially be significant to the legal entity and (2) the power to direct the activities that most significantly affect the other legal entity.

After more than four decades of little change, the accounting guidance on consolidation has been evolving rapidly over the past 15 years. **ASU 2015-02** is the latest chapter in the consolidation evolution story. While the ASU did not introduce any new models, its changes eliminated two of the existing models (FIN 46(R) and EITF Issue 04-5), requiring all entities to be evaluated as either a voting interest entity or a VIE. Further, under the ASU, the evaluation of whether a VIE should be consolidated is still based on whether the reporting entity has both (1) power and (2) potentially significant economics.

Key changes under ASU 2015-02 include the following:

- The Statement 167 deferral for interests in investment companies (and certain similar entities) has been eliminated, thereby removing the risks-and-rewards-based consolidation model under FIN 46(R) from U.S. GAAP.
- The limited partnership model in ASC 810-20 has been eliminated. Instead, limited partnerships will be VIEs unless the limited partners have substantive kick-out or participating rights. Although more limited partnerships will be VIEs, it is less likely that a general partner will consolidate a limited partnership.
- The guidance on fees paid to a decision maker or service provider has been amended. Specifically, it is less likely that the fees themselves would be considered a variable interest, that a legal entity would be a VIE, or that a decision maker would consolidate the legal entity.
- ASU 2015-02 significantly amends how variable interests held by a reporting entity’s related parties or de facto agents affect its consolidation conclusion. In addition, the ASU will result in less frequent performance of the related-party tiebreaker test (and mandatory consolidation by one of the related parties) than under the previous VIE models.

ASC 810-10-05-6 contains a flowchart that consists of a series of decision trees to help reporting entities identify (1) which consolidation model to apply, if any; (2) whether a reporting entity should consolidate a VIE; and (3) whether a reporting entity should consolidate a voting interest entity. See Deloitte’s **A Roadmap to Consolidation — Identifying a Controlling Financial Interest** (the “Consolidation Roadmap”) for a flowchart that incorporates the concepts in the FASB’s flowchart and serves as a guide to the consolidation accounting literature.
ASU 2015-02 affects all entities with variable interests in other entities. Reporting entities must document their considerations of the new guidance and how it affects any previous consolidation conclusions or their identification of other legal entities as VIEs. For PBEs, the guidance in ASU 2015-02 became effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. For entities other than PBEs, the guidance became effective for annual periods beginning after December 15, 2016, and interim periods beginning after December 15, 2017.

After issuing ASU 2015-02, the FASB issued ASU 2016-17, which amends the guidance in ASU 2015-02 on interests held through related parties that are under common control in the assessment of whether a reporting entity has a potentially significant interest in a legal entity. Under ASU 2015-02 before the adoption of ASU 2016-17, a reporting entity that held an interest in another entity under common control was required to consider that related party’s interest in a VIE as its own (e.g., if the related party held a 40 percent interest in the VIE, the reporting entity would include the full 40 percent interest in its assessment even if it held only a nominal interest in the related party). Under ASU 2016-17, a reporting entity considers its indirect economic interests in a VIE held through related parties that are under common control on a proportionate basis, in a manner consistent with its consideration of its indirect economic interests held through related parties that are not under common control. For further information, see Deloitte’s November 1, 2016, Heads Up.

Industry Issues

The discussions and examples below contain guidance on consolidation matters that frequently affect life sciences entities. The guidance cited is not intended to be all-inclusive or comprehensive; rather, it provides targeted considerations related to the application of ASU 2015-02 that are most relevant to the industry. To complete a consolidation analysis, entities must consider all facts and circumstances and use significant judgment. The examples cited will be beneficial in introducing concepts as you approach any newly acquired variable interests or perform reassessments under the new standard’s amendments to existing guidance.

Scope Exceptions to the Consolidation Guidance — Business Scope Exception

A reporting entity should evaluate whether it can apply any of the general scope exceptions to the consolidation guidance or the scope exceptions to the VIE model. The most frequently cited exception is the so-called business scope exception. (For a list of all consolidation and VIE scope exceptions, see Chapter 3 of Deloitte’s Consolidation Roadmap.)

The business scope exception is two-pronged and premised on both (1) the legal entity's characteristics (i.e., the nature of the legal entity's activities and whether it is a business as defined in ASC 805, and (2) the reporting entity's relationship with the legal entity (e.g., the extent of involvement by the reporting entity in the design or redesign of the legal entity, whether the legal entity is designed so that substantially all of its activities either involve or are conducted on behalf of the reporting entity and its related parties, and whether the reporting entity and its related parties provided more than half of the subordinated financial support.) A common oversight in evaluating the applicability of the business scope exception is merely assessing whether a legal entity meets the definition of a business and failing to assess the nature of the legal entity’s activities and the conditions outlined in the second prong of the test. Two of the more common relationships that must be analyzed are described below.

---

1 As further discussed in the Clarifying the Definition of a Business section, ASU 2017-01 narrows the definition of a business and is intended to reduce the number of legal entities that will be deemed businesses once the standard is adopted. We do not believe that a reporting entity is generally required upon adoption of ASU 2017-01 to reassess whether a legal entity that previously applied the business scope exception continues to meet the definition of a business.
**Substantially All of the Activities Either Involve or Are Conducted on Behalf of the Reporting Entity**

A reporting entity should base its determination of whether substantially all of a legal entity’s activities either involve or are conducted on behalf of the reporting entity and its related parties on the design of the legal entity and should compare the nature and extent of the activities between the reporting entity and the legal entity with the entire set of the legal entity’s activities. Generally, if 90 percent or more of the legal entity’s activities are conducted on behalf of a reporting entity and its related parties, it is presumed to be “substantially all” of the legal entity’s activities. However, less than 90 percent is not a safe harbor. While a variety of circumstances may indicate that substantially all of the activities of a legal entity are conducted on behalf of a reporting entity, in the context of the life sciences industry, one such circumstance would be when a reporting entity holds the rights to products that result from the R&D of a legal entity.

**Example 1**

A joint venture entity (Entity P) is formed by two unrelated parties, Enterprises U and G. Each investor has a 50 percent equity interest. Entity P’s activities consist solely of developing pharmaceutical products, and the reporting entity, U, has the rights to the resulting products. As currently designed, P represents a development arm of U’s business because it is so closely aligned with U in appearance and purpose. Therefore, substantially all of P’s activities either involve or are conducted on behalf of U and, accordingly, the business scope exception cannot be applied by U.

**Additional Subordinated Financial Support — Put and Call Options**

Put and call options may exist in agreements between equity owners in a life sciences legal entity (e.g., between joint venture partners). Such options can have an impact on whether a reporting entity meets the condition in ASC 810-10-15-17(d)(3) and, therefore, on whether the reporting entity can apply the business scope exception. The examples below illustrate situations in which (1) a put option (purchased by one investor from the reporting entity) results in the reporting entity’s ineligibility for the business scope exception since the reporting entity effectively provides more than half of the total equity, subordinated debt, and other forms of subordinated financial support to the legal entity and (2) a call option would not have the same impact.

**Example 2**

**Put Option**

Investor A and Investor B form Entity X with equal contributions of equity. Investor B purchases a put option from A that permits it to put its interest in X to A at a fixed price.
Example 2 (continued)

The fair value of the fixed-price put option should be considered additional subordinated financial support provided by A to X because A will absorb expected losses of X upon exercise of that put option (i.e., it meets the definition of subordinated financial support in ASC 810-10-20). Therefore, A would consider the fair value of the fixed-price put option (presumably the price paid) in determining whether the condition in ASC 810-10-15-17(d)(3) is met. If the fair value of the put option is greater than zero, A would meet this condition and therefore would not be able to use the business scope exception since the fair value of the equity provided by A and the fair value of the put option written by A would constitute more than half the total of the equity, subordinated debt, and other forms of subordinated financial support to the legal entity.

Example 3

Call Option

Investor A and Investor B form Entity X with equal contributions of equity. Investor A purchases a call option from B that permits it to call B’s interest at a fixed price (the call option’s strike price is at or above the fair value of the equity interest at inception of the option).

Investor A

Fixed-Price Purchased Call Option

Investor B

50% Owned

50% Owned

Entity X

The fair value of the fixed-price call option should not be considered additional subordinated financial support to X because A will not absorb expected losses of X upon exercise of that call option (i.e., the option does not meet the definition of subordinated financial support in ASC 810-10-20). Investor A can exercise its call and obtain additional residual returns of X, but the call option does not expose it to additional expected losses. Therefore, A would not consider the fair value of the fixed-price call option in determining whether it meets the condition in ASC 810-10-15-17(d)(3). Investors A and B would not meet this condition since the fair value of the equity provided by each investor would not constitute more than half of the total of the equity, subordinated debt, and other forms of subordinated financial support to the legal entity. To use the business scope exception, A and B must determine whether any of the other conditions in ASC 810-10-15-17(d) are met.

Identifying Variable Interests

One of the first steps in assessing whether a reporting entity is required to consolidate another legal entity is to determine whether a reporting entity holds a variable interest in the legal entity being evaluated for consolidation. If a reporting entity does not have a variable interest in the legal entity, no further analysis is required. That is, that reporting entity is not required to consolidate the legal entity or provide any of the VIE disclosures related to the legal entity. While there are many forms of variable interests, all variable interests will absorb portions of an entity’s variability (changes in the fair value of the entity’s net assets) that the legal entity was designed to create. An interest that creates variability would not be considered a variable interest.

The FASB established a two-step “by-design” approach for the identification of variable interests. Under this approach (ASC 810-10-25-22), the reporting entity would (1) “analyze the nature of the risks in the legal entity” and (2) “determine the purpose(s) for which the legal entity was created and determine the variability (created by the risks identified in Step 1) the legal entity is designed to create and pass along to its interest holders.” ASC 810-10-20 defines variable interests in a VIE as “contractual, ownership, or other pecuniary interests in a VIE that change with changes in the fair value of the VIE’s net assets exclusive of variable interests.”
It is often simple to determine whether an arrangement is a variable interest. A good rule of thumb is that most arrangements on the credit side of the balance sheet (e.g., equity and debt) are variable interests because they absorb variability as a result of the performance of the legal entity. However, determining whether other arrangements (e.g., derivatives, leases, and decision-maker and other service-provider contracts) are variable interests can be more complex. The table below contains a very limited list of examples of what may be considered variable interests.

<table>
<thead>
<tr>
<th>Types of Variable Interests</th>
<th>Illustrative Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term liabilities of a legal entity (e.g., fixed-rate debt, floating-rate debt, mandatorily redeemable preferred stock)</td>
<td>Aspen Co. (the reporting entity) lends Dunne Co., a biotech firm, $50 million in the form of a five-year fixed-rate unsecured loan. Aspen Co., as a debt holder, absorbs the variability in the value of the legal entity's net assets exclusive of variable interests because Aspen Co. is exposed to Dunne Co.'s ability to pay (i.e., credit risk) and may also be exposed to interest rate risk depending on the design of the legal entity.</td>
</tr>
<tr>
<td>Equity of a legal entity (e.g., mezzanine equity, preferred stock, common stock, partnership capital)</td>
<td>Schrute LP (the reporting entity) invests $89 million in Michael Co., a CRO. The equity investment was made in common stock and is considered equity at risk under ASC 810-10-15-14(a) (which is further discussed below). Schrute LP's interest in Michael Co. is a variable interest that absorbs the variability associated with changes in Michael Co.'s net assets exclusive of variable interests.</td>
</tr>
<tr>
<td>Guarantees written by a reporting entity&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Costanza Inc. (the reporting entity) provides a guarantee to a medical device company, Ball Investments Inc., on the $2 billion fair value of all medical device IP held by Ball Investments Inc. Costanza Inc. must pay Ball Investments Inc. for any decreases in value of this IP. The guarantee agreement transfers all or a portion of the risk of specified assets (IP) to Costanza Inc.; thus, Costanza Inc. has a variable interest in Ball Investments Inc.</td>
</tr>
<tr>
<td>Put options written by a reporting entity and similar arrangements on specified assets owned by the legal entity&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Hermanos LLC (the reporting entity) writes a put option to White Inc. allowing White Inc. to sell its medicinal compound in development for a fixed price at a later date. Hermanos LLC has a variable interest in the specified assets of White Inc. since Hermanos LLC is exposed to variability in the values of the medicinal compound.</td>
</tr>
<tr>
<td>Stand-alone call options written by the legal entity on specified assets owned by that legal entity&lt;sup&gt;4&lt;/sup&gt;</td>
<td>Sterling Inc. writes a call option on its wholly owned interest in a treatment in phase II clinical trials to Draper LP (the reporting entity), allowing Draper LP to acquire the interest for a fixed price at a later date. Because Draper LP participates in the positive variability of the specified assets of Sterling Inc., Draper LP possesses a variable interest in those specified assets.</td>
</tr>
</tbody>
</table>

---

<sup>2</sup> ASC 810-10-25-55 and 25-56 indicate that variable interests in a specified asset whose value is less than half of the total fair value of a VIE's assets are not considered variable interests in that legal entity unless the reporting entity also holds another interest in the legal entity. In addition, a variable interest in a specified asset of a VIE could result in consolidation of a “silo” within the VIE. For further discussion, see Section 4.3.11 and Chapter 6 of Deloitte’s Consolidation Roadmap.

<sup>3</sup> See footnote 2.

<sup>4</sup> See footnote 2.
(Table continued)

<table>
<thead>
<tr>
<th>Types of Variable Interests</th>
<th>Illustrative Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fees paid to a decision maker or service provider</td>
<td>Snow LLC pays a fee to Red Corp. (the reporting entity) to distribute Snow LLC’s products. The fee arrangement requires Snow LLC to pay Red Corp. all profits earned on the distribution of the products. In accordance with ASC 810-10-55-37C, the fee arrangement is designed to transfer substantially all of the residual returns and risks of ownership of Snow LLC’s products to Red Corp., the decision maker. Red Corp.’s earned fee represents a variable interest in Snow LLC.</td>
</tr>
<tr>
<td>Royalties and licenses paid to a reporting entity</td>
<td>Caspian Inc. (the reporting entity) holds rights to a pharmaceutical drug. Wilson Inc. obtains a license from Caspian Inc. to produce, market, and sell the drug, and Caspian Inc. will earn a royalty based on Wilson Inc.’s sales. Caspian Inc. holds a variable interest in Wilson Inc. because it absorbs variability through the royalty.</td>
</tr>
</tbody>
</table>

The table below lists examples of what generally would not be considered variable interests.

<table>
<thead>
<tr>
<th>Types of Nonvariable Interests</th>
<th>Illustrative Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets of the legal entity</td>
<td>David Inc. (the reporting entity) owes $100 million to Prettay LP as part of an existing loan agreement. Although the loan receivable asset generates value to the investors of Prettay LP, the loan receivable is not a variable interest to David Inc. Assets of a legal entity typically are the major source of a legal entity’s variability, not an absorber of variability, and are therefore not considered variable interests.</td>
</tr>
<tr>
<td>Contingent payments made to a legal entity</td>
<td>Ernie Pharmaceuticals Inc. (the reporting entity) enters into an agreement with Clementine LLC to continue the R&amp;D of a phase I drug held by Clementine LLC. In exchange for the drug’s achievement of milestones, such as FDA approval and the achievement of specified sales levels, Ernie Pharmaceuticals Inc. will make milestone payments and pay Clementine LLC royalties. Ernie Pharmaceuticals Inc. is not exposed to the variability in Clementine LLC and therefore does not possess a variable interest through its milestone or royalty payments.</td>
</tr>
</tbody>
</table>

Discussion of the by-design approach for identifying variable interests, along with a more expansive list of illustrative examples of variable interests, is included in Chapter 4 of Deloitte’s Consolidation Roadmap.

**Determining Whether a Legal Entity Is a VIE**

To determine which consolidation model to apply when evaluating its variable interest in a legal entity, a reporting entity must determine whether the legal entity is a VIE. This determination must be made upon the reporting entity's initial involvement with the legal entity and reassessed upon the occurrence of a reconsideration event.

Legal entities can differ in structure as well as legal form (e.g., corporations compared with limited partnerships and similar entities), which affects the method used to understand their design and purpose. In simple terms, the distinction is based on the nature and amount of the equity investment and the rights and obligations of the equity investors.
To qualify as a VIE, a legal entity needs to satisfy only one of the following characteristics:

- The legal entity does not have sufficient equity investment at risk.
- The equity investors at risk, as a group, lack the characteristics of a controlling financial interest.
- The legal entity is structured with disproportionate voting rights, and substantially all of the activities are conducted on behalf of an investor with disproportionately few voting rights.

Below is a brief list of considerations specifically relevant to life sciences entities for determining whether the legal entity is a VIE. Since this list is not all-encompassing, we encourage you to refer to Chapter 5 of Deloitte's Consolidation Roadmap during your analysis.

**The Legal Entity Does Not Have Sufficient Equity Investment at Risk**

If a legal entity has sufficient equity investment at risk to finance its operations, and the holders of equity investment at risk make decisions that direct the significant activities of the legal entity, consolidation based on majority voting interest is generally appropriate. However, if equity investment at risk is not sufficient, or the holders of equity investment at risk do not control the legal entity through their equity investment at risk, the VIE model is used to identify the appropriate party, if any, to consolidate.

**Determining Whether the Equity Investment Is “At Risk”**

An interest classified as equity may not have the substantive characteristics of equity. Since the VIE consolidation framework is intended to apply to entities whose voting interests may not be the most appropriate determining factor, the FASB reasoned that equity interests that are not “at risk” should not be included in the sufficiency-of-equity test. To be considered part of the equity investment at risk, equity interests must (1) participate significantly in profits and losses, (2) not be issued in exchange for subordinated interests in other VIEs, (3) not be received from the legal entity or parties involved with the legal entity (see example below), and (4) not be financed by the legal entity or other parties involved with the legal entity. Further, equity investments acquired by an equity investor in exchange for promises to perform services cannot be considered equity investment at risk since the equity is received in lieu of a fee for services to be performed. Similarly, equity investments acquired as a result of past services performed are not considered equity investment at risk.

**Example 4**

Three investors form Entity X to conduct R&D activities. Entity X issues equity with a par amount of $15 million ($5 million to each investor). Investor A contributes $5 million in cash. Investor B issues a guarantee that the fair value of the compound at the completion of the R&D activities will be at least $90 million. Investor C enters into an agreement with X to provide research scientists who will work for 500 hours to complete the activities.

Only A's $5 million in equity is considered equity at risk because B and C received their equity as payment from X for the guarantee (promise to stand ready) and the performance of services, respectively.
Determining Whether the Identified Equity Investment at Risk Is Sufficient to Finance the Legal Entity's Operations Without Additional Subordinated Financial Support

Once the amount of equity investment at risk is quantified, a reporting entity must determine whether the equity investment at risk is sufficient to finance the legal entity's operations without additional subordinated financial support. If not, the legal entity is a VIE. The purpose of this assessment is to identify whether a legal entity is sufficiently capitalized. Merely having at-risk equity is not enough; the legal entity must be able to finance its operations with the equity investment at risk. The reporting entity must use judgment to determine sufficiency since the various risk tolerances, investment objectives, and liquidity requirements of investing can influence the level of capital in a legal entity.

Existence of Subordinated Debt

In the evaluation of whether equity investment at risk is sufficient, consideration should also be given to whether the entity has outstanding, or could issue, investment-grade debt since such debt is typically issued only when third parties deem a legal entity to be sufficiently capitalized. If debt is subordinated to other variable interests, equity investment at risk may be insufficient to finance the legal entity's operations. The determination of whether debt represents subordinated financial support is based on how that debt absorbs expected losses compared with other variable interests in the legal entity. If the terms of the debt arrangement cause the debt to absorb expected losses before or at the same level as the most subordinated interests (e.g., equity, other subordinated debt), or the most subordinated interests are not large enough to absorb the legal entity's expected losses, the debt would generally be considered subordinated financial support. However, investment-grade debt is a variable interest that would generally not be considered subordinated financial support because investment-grade debt generally indicates that third parties deem the legal entity to be sufficiently capitalized.

Example 5

Entity D is formed with $50 of equity and $50 of long-term debt. The long-term debt consists of two issuances: Debt A, $45; and (2) Debt B, $5. Debt B is subordinate to Debt A. Because D was recently formed, it could not obtain senior debt (Debt A) in an investment-grade form.

In a qualitative assessment, the existence of subordinated debt is a factor indicating that D does not have sufficient equity at risk. That factor should be considered along with all other facts and circumstances (e.g., a 50 percent ratio of equity at risk frequently exceeds expected losses). If the qualitative assessment is inconclusive, a quantitative analysis (i.e., calculation of expected losses/residual returns) should be performed to determine whether D is a VIE.

Assume that D was a VIE at formation. Two years after its formation, D engages in additional business activities beyond those that were considered at formation and is an established, profitable business. Given its desire to further expand its business, D issues a new tranche of debt (Debt C) whose rank is identical in seniority (e.g., priority in liquidation) to that of Debt B. Because D's stable financial condition, the tranche of debt is rated investment-grade. Given the identical priority in liquidation of Debt B and Debt C, one can infer that Debt A (which is senior to Debt B) and Debt B would be rated investment-grade as well. No other debt securities are outstanding, and no other evidence of subordinated financial support (e.g., guarantees) is noted. Assume that a reconsideration event under ASC 810-10-35-4(c) has occurred because the additional business activities increase D's expected losses. Therefore, the variable interest holders must determine whether D is still a VIE.

In a qualitative assessment, D's ability to issue investment-grade debt that has the same priority in liquidation as Debt A and Debt B is one factor indicating that D, as of the reconsideration date, has sufficient equity at risk. That is, in the absence of other forms of subordinated financial support, D would not have been able to obtain an investment-grade rating on the new debt if its existing equity at risk was not sufficient. However, all other facts and circumstances existing as of the reconsideration date should be considered. If the qualitative assessment is not conclusive, a quantitative analysis should be performed to determine whether D is a VIE as of the reconsideration date.
Development-Stage Entities

Since life sciences entities frequently require varying levels of funding to complete a product candidate's R&D, it is important for such entities to understand the "sufficiency of the equity investment at risk" characteristic in the VIE analysis when evaluating the funding of each R&D phase.

Recognizing the unique funding needs of early-stage entities, the FASB formerly provided a different framework (the "specialized approach") for evaluating the sufficiency of equity investment at risk for all development-stage entities. Under the specialized approach, which has been superseded by ASU 2014-10, ASC 915-10-20 contained the following definition of a development-stage entity:

An entity devoting substantially all of its efforts to establishing a new business and for which either of the following conditions exists:

a. Planned principal operations have not commenced.

b. Planned principal operations have commenced, but there has been no significant revenue therefrom.

Before the adoption of ASU 2014-10, the following two conditions needed to be present for equity investment at risk to be considered sufficient for a development-stage entity:

• The legal entity must have had sufficient equity to fund its current developmental activity.

• The legal entity must have been legally structured to permit additional equity investment in the future, to fund further development upon completion of the current activity.

This framework was more generous than the approach applicable to entities that did not qualify as development-stage entities since it took into account the life cycle of the legal entity in phases rather than over the entire contemplated life of the legal entity. However, the specialized approach applied only to the sufficiency of equity investment at risk; an assessment of the other conditions of a VIE still needed to be performed for such legal entities.

Under this framework, a reporting entity (1) initially assessed whether a development-stage entity was a VIE on the date the reporting entity first became involved with the legal entity and (2) reconsidered its assessment upon the occurrence of any of the events described in ASC 810-10-35-4. For a development-stage entity, such events would include, but not be limited to:

• Funding of additional equity.

• Commencement of additional activities (e.g., entering a subsequent “phase” of development).

Although ASU 2014-10 removed the concept of a development-stage entity, we believe that it is still necessary to consider the design of a legal entity in the determination of whether the legal entity's equity investment at risk is sufficient. That is, for certain legal entities that met the definition of a development-stage entity under previous guidance, considering only the legal entity's current stage of development may be appropriate in the assessment of sufficiency of equity. Specifically, if a legal entity is in the development stage and there is substantial uncertainty about whether the legal entity will proceed to the next stage, it may be appropriate to consider only the current stage in the sufficiency assessment. This approach is consistent with the assessment of power in the primary-beneficiary analysis of a multiple-stage entity.

---

5 ASU 2014-10 eliminated the specialized approach for considering sufficiency of equity investment at risk for development-stage entities. That ASU became effective for PBEs for annual periods beginning after December 15, 2015, and interim periods therein. For entities other than PBEs, ASU 2014-10 became effective for annual periods beginning after December 15, 2016, and interim periods beginning after December 15, 2017. As a result of these effective dates and early adoption, virtually all entities have adopted ASU 2014-10. Reporting entities that have historically applied the specialized approach should consider the impact of ASU 2014-10 on their historical conclusions.
Example 6

Entity D is a development-stage entity. Investor A and Investor B each contributed $1 million of equity financing to D. Entity D’s current activities consist of product development and marketing surveys (“phase I”). Upon successful completion of phase I, D plans to commence test marketing (i.e., selling these products in selected areas) (“phase II”). During the final phase of D’s development stage, it plans to engage in limited-scale production and selling efforts (“phase III”). Entity D’s by-laws allow A and B to fund additional equity upon the completion of phase I and phase II.

In the assessment of whether D has sufficient equity at risk under ASC 810-10-15-14(a), only the current phase of D’s development needs to be considered. Thus, if, at inception, the $2 million of equity capital is deemed sufficient to finance phase I, D would be considered to have sufficient equity investment at risk. This determination should be reassessed at the commencement of phase II and phase III, upon the funding of additional equity financing, or upon the occurrence of any of the events in ASC 810-10-35-4.

Equity Investors, as a Group, Lack the Characteristics of a Controlling Financial Interest

The manner in which a reporting entity determines whether it holds a controlling financial interest in a legal entity under the VIE model is different from how it makes the determination under the voting interest entity model. The voting interest entity model focuses on the voting rights conveyed by equity interests. Since the holder of an interest other than equity may control the legal entity, the voting interest entity model may not yield an appropriate consolidation conclusion if the equity interests collectively do not possess the characteristics that are typical of equity interests. Accordingly, a legal entity is considered a VIE if any of the following three qualities — the “typical” characteristics of an equity investment — are absent from the holders of equity investment at risk as a group:

- The power to direct the most significant activities of the legal entity.
- The obligation to absorb the expected losses of the legal entity.
- The right to receive the expected residual returns of the legal entity.

The rights of the equity investment at risk investor group must be a characteristic of the equity investment at risk itself and not a characteristic of other interests held by the current holders of the equity investment at risk. It is not necessary for each individual equity investment at risk to possess all three characteristics, but the total equity investment at risk must possess them all. By implication, as long as the group of at-risk equity investors possesses these three characteristics through their equity investment at risk, the failure of any one at-risk equity investor to possess the characteristics would not make the legal entity a VIE.

Example 7

Stabler Inc. holds the patent to a phase II drug, which represents 80 percent of the fair value of the assets held by Stabler Inc. Stabler Inc. issues to Benson LLC a fixed-price call option on the phase II drug that is exercisable in one year. The right of Stabler Inc. to receive the expected residual returns is effectively capped because of Benson LLC’s ability to participate in the upside through its call option. Consequently, Stabler Inc. is a VIE.
**Disproportionate (Nonsubstantive) Voting Rights**

Although intended to clarify the previous criteria (at-risk equity investors as a group do not possess characteristics of a controlling financial interest), the evaluation of whether disproportionate (nonsubstantive) voting rights exist is generally considered a separate condition in the assessment of a VIE. ASC 810-10-15-14(c)(2) explains that the provision “is necessary to prevent a primary beneficiary from avoiding consolidation of a VIE by organizing the legal entity with nonsubstantive voting interests.” Thus, ASC 810-10-15-14(c) is referred to as the “anti-abuse provision” since it aims to prevent a legal entity from being structured in a manner such that the legal entity does not confer voting control to a reporting entity but in substance should be consolidated by the reporting entity because “substantially all” of the legal entity’s activities either involve the reporting entity or are conducted on the reporting entity’s behalf. See Section 5.4 of Deloitte’s Consolidation Roadmap for more interpretive guidance on evaluating this criterion.

**SEC Comment Letters Related to the Determination of Whether a Legal Entity Is a VIE**

**Example of an SEC Comment**

We note from your prior response that you believe you should consolidate [the legal entity] under either the variable interest or voting interest models. Please tell us how you considered ASC 810-10-15-14 in determining whether [the legal entity] has the characteristics of a variable interest entity.

Given that the variable interest model is complex and requires an entity to use significant judgment, the SEC staff frequently requests further information from registrants about how they concluded that an entity either is or is not a VIE.

**Identifying the Primary Beneficiary of a VIE**

The primary beneficiary of a VIE is the party required to consolidate the VIE (i.e., the party with a controlling financial interest in the VIE). Upon the adoption of ASU 2015-02, the analysis for identifying the primary beneficiary is consistent for all VIEs. Specifically, ASC 810-10-25-38A requires the reporting entity to perform an assessment that focuses on whether the reporting entity has both “power” and “economics.” These two concepts are discussed below. For more detailed information, see Chapter 7 of Deloitte’s Consolidation Roadmap.

**Power Criterion**

Although identification of the primary beneficiary requires an evaluation of both characteristics of a controlling financial interest in a VIE, the determination is often based on which variable interest holder satisfies the power criterion since generally more than one variable interest holder meets the economics criterion.

To determine whether it meets the power criterion, the reporting entity must identify the activities that most significantly affect the VIE’s economic performance and then determine which variable interest holder has the power to direct those activities. The reporting entity would take the following steps to identify the party with the power to direct the activities that most significantly affect the VIE’s economic performance:

- **Step 1** — Evaluate the purpose and design of the VIE and the risks the VIE was designed to create and pass along to its variable interest holders.
Consolidation

• **Step 2** — Identify the significant decisions related to the risks identified in step 1 and the activities associated with those risks. In certain situations in which multiple unrelated variable interest holders direct different decisions and activities, the reporting entity must determine which activity most significantly affects the VIE’s economic performance. The party that has the power to direct such activity will meet the power criterion. When making this determination, the reporting entity should consider the activity that results in the most economic variability for the VIE (e.g., expected losses and expected residual returns).

• **Step 3** — Identify the party that makes the significant decisions or controls the activity or activities that most significantly affect the VIE’s economic performance. Consider whether any other parties have involvement in those decisions (shared power) or can remove the decision maker (kick-out rights).

While a VIE often performs a variety of activities, the key to determining whether the power criterion has been satisfied is identifying the activities that are most significant to the VIE’s economic performance.

**Contingencies**

Future power can be conveyed to a variable interest holder upon the occurrence of a contingent event. Questions have arisen about whether such a variable interest holder can be the primary beneficiary of the VIE before the occurrence of that contingent event. When a party can direct activities only upon the occurrence of a contingent event, the determination of which party has power will require an assessment of whether the contingent event results in a **change in power** (i.e., power shifts from one party to another upon the occurrence of a contingent event) over the most significant activities of the VIE (in addition, the contingent event may change what the most significant activities of the VIE are) or whether the contingent event **initiates** the most significant activities of the VIE (i.e., the VIE’s most significant activities occur only when the contingent event happens).

<table>
<thead>
<tr>
<th>Example 8</th>
</tr>
</thead>
</table>

Entity X is formed by two investors (A and B) to develop and manufacture a new drug. Assume that X is a VIE and that each investor holds a variable interest in X. Investor A has power over the R&D activities to develop and obtain FDA approval for the drug (stage 1), and those activities most significantly affect X’s economic performance during that stage. Investor B has the power over the manufacturing process, distribution, and marketing of the drug (as well as protecting its patented formula) if and when FDA approval is obtained (stage 2), and those activities would most significantly affect X’s economic performance during that stage. In determining which investor has the power to direct the activities that most significantly affect the economic performance of X, each investor should assess whether the contingent event (FDA approval) results in a change in power over the most significant activities of X (in addition, the contingent event may change what the most significant activities of X are) or whether the contingent event initiates the most significant activities of X.

Entity X was designed in such a way that there are two distinct stages during its life, and the variable interest holders expect that the second stage will begin only upon FDA approval. Also, the activities and decisions before and after FDA approval are significant to the economic performance of X (in this example, they are different activities directed by different parties). In addition, the variable interest holders conclude that there is substantial uncertainty about whether FDA approval will be obtained and that the approval is outside their control. For these reasons, in the absence of evidence to the contrary, FDA approval would be considered a substantive contingent event that results in a change in power from A to B. Therefore, the primary-beneficiary determination should focus on stage 1 activities until the contingent event occurs, and A (the investor that has the power over the R&D activities) would initially have the power to direct the most significant activities of X. If FDA approval is obtained, the primary-beneficiary determination would focus on stage 2 activities, and B (the variable interest holder that has the power over the manufacturing process, distribution, and marketing of the drug) would have the power to direct the most significant activities of X.
Economics Criterion

To satisfy the economics criterion in the analysis of the primary beneficiary of a VIE, the variable interest holder must have the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. Said simply, the variable interest holder must have an exposure to the economics of the VIE that is more than insignificant. As a general guideline, the economics criterion would be met if the losses or returns that could potentially be absorbed or received through the reporting entity’s variable interests in the VIE exceed, either individually or in the aggregate, 10 percent of the losses or returns of the VIE under any scenario. However, 10 percent should not be viewed as a bright line or safe harbor. That is, as a result of facts and circumstances, a reporting entity may conclude that the economics condition is met even if the losses or returns absorbed or received by the reporting entity’s interests in the VIE are less than 10 percent. Because the threshold for meeting the economics criterion is low, most of the primary-beneficiary analysis is focused on assessing the reporting entity’s power over the significant activities that affect the VIE’s performance.

SEC Comment Letters Related to the Primary-Beneficiary Assessment

Example of an SEC Comment

Please describe to us the changes in the capital structure of [the legal entity] and in its contractual relationships with [you, as the reporting entity] that resulted in your conclusion that you are no longer its primary beneficiary and that you should deconsolidate [the legal entity] as of January 3, 2016. Explain to us in appropriate detail how these specific changes support your conclusion that you are no longer the primary beneficiary of the variable interest entity. Refer to the guidance provided in ASC 810-10, including ASC 810-10-35-4.

Because the primary-beneficiary assessment determines whether a registrant will consolidate an entity, the SEC staff will often request further information from registrants about their primary-beneficiary assessment.

Other Considerations

Example of an SEC Comment

We note you consolidate entities in which you have a variable interest and of which you are the primary beneficiary. Please tell us what consideration you gave to disclosing the information required by ASC 810-10-50-2AA regarding your involvement with variable interest entities, the information required by ASC 810-10-50-3 with respect to variable interest entities you consolidate as the primary beneficiary and the information required by ASC 810-10-50-4 with respect to variable interest entities you do not consolidate because you are not the primary beneficiary.

All reporting entities that have a variable interest in a VIE are subject to the disclosure requirements of ASC 810-10. Reporting entities should consider the overall objectives of ASC 810-10-50-2AA and, depending on the circumstances, may need to supplement their disclosures to meet these objectives. Meeting the disclosure requirements can sometimes be challenging because a reporting entity might not be privy to all the information about a VIE, especially if the reporting entity is not the primary beneficiary of the VIE but has a variable interest in the VIE and is subject to some of the VIE’s disclosure requirements. Given the nature of variable interests often held by life sciences entities in VIEs, it is important for life sciences entities to keep these disclosure requirements in mind when preparing financial statements.
Because this publication is intended to highlight some of the complex issues frequently encountered by life sciences entities, certain consolidation topics are outside its scope. However, such topics are discussed in Deloitte’s Consolidation Roadmap; they include, but are not limited to, (1) the assessment of related parties in the identification of variable interests and performance of the primary-beneficiary analyses, (2) consolidation evaluations involving voting interest entities, and (3) special considerations related to limited partnerships and similar entities. For a summary of the key changes to ASC 810 as a result of ASU 2015-02, see Appendix A of the Consolidation Roadmap.

Further, for additional discussion of R&D funding arrangements that involve legal entities, refer to the R&D Funding Arrangements section above.

New Accounting Standard
As discussed above in the Clarifying the Definition of a Business section, the FASB has issued ASU 2017-01, which effectively narrows the definition of a business. As a result, fewer entities may qualify for the business scope exception.

On the Horizon
On June 22, 2017, the FASB issued a proposed ASU on targeted improvements to the related-party guidance in ASC 810. The proposed ASU’s three main objectives are to (1) add an elective private-company scope exception to the VIE guidance for entities under common control; (2) remove a sentence in ASC 810-10-55-37D regarding the evaluation of fees paid to decision makers to conform the guidance in that paragraph with the amendments in ASU 2016-17 (issued in October 2016); and (3) make additional changes to the related-party guidance in the VIE primary-beneficiary assessment, including amendments to ASC 810-10-25-44 (frequently referred to as the related-party tiebreaker test). Comments on the proposed ASU were due by September 5, 2017. For additional information, see Deloitte’s July 14, 2017, Heads Up.

On September 20, 2017, the FASB issued a proposed ASU that would reorganize the consolidation guidance in ASC 810 by creating a new Codification topic, ASC 812, with separate sections for the guidance on (1) the VIE model and (2) the voting interest entity model. The proposed ASU states that its goal is to make “navigating and understanding consolidation guidance easier without affecting how consolidation analyses are currently performed.” Comments on the proposed ASU were due by December 4, 2017. For additional information, see Deloitte’s October 5, 2017, Heads Up.
Appendix A — Glossary of Standards and Other Literature

The standards and other literature below were cited or linked to in this publication.

**AICPA Literature**

Accounting and Valuation Guide *Assets Acquired to Be Used in Research and Development Activities*

AICPA Issues Paper, *Identification and Discussion of Certain Financial Accounting and Reporting Issues Concerning LIFO Inventories*

*AICPA Technical Questions and Answers*, Q&A paragraph 2260.03, “Other Assets; Legal Expenses Incurred to Defend Patent Infringement Suit”

**FASB Accounting Standards Updates (ASUs)**


ASU 2018-01, *Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842*

ASU 2017-12, *Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities*

ASU 2017-11, *Earnings per Share (Topic 260); Distinguishing Liabilities From Equity (Topic 480); Derivatives and Hedging (Topic 815); (Part I) Accounting for Certain Financial Instruments With Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception*

ASU 2017-09, *Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting*

ASU 2017-07, *Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*

ASU 2017-05, *Other Income — Gains and Losses From the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets*

ASU 2017-04, *Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment*

ASU 2017-01, *Business Combinations (Topic 805): Clarifying the Definition of a Business*
ASU 2016-20, *Technical Corrections and Improvements to Topic 606, Revenue From Contracts With Customers*


ASU 2016-17, *Consolidation (Topic 810): Interests Held Through Related Parties That Are Under Common Control*

ASU 2016-16, *Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory*


ASU 2016-13, *Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*

ASU 2016-12, *Revenue From Contracts With Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients*

ASU 2016-11, *Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Recission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting*

ASU 2016-10, *Revenue From Contracts With Customers (Topic 606): Identifying Performance Obligations and Licensing*

ASU 2016-09, *Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting*

ASU 2016-08, *Revenue From Contracts With Customers (Topic 606): Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)*

ASU 2016-02, *Leases (Topic 842)*


ASU 2015-14, *Revenue From Contracts With Customers (Topic 606): Deferral of the Effective Date*

ASU 2015-02, *Consolidation (Topic 810): Amendments to the Consolidation Analysis*


ASU 2014-16, *Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity — a consensus of the FASB Emerging Issues Task Force*

ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation

ASU 2014-09, Revenue From Contracts With Customers (Topic 606)

ASU 2014-02, Intangibles — Goodwill and Other (Topic 350): Accounting for Goodwill — a consensus of the Private Company Council

ASU 2011-06, Other Expenses (Topic 720): Fees Paid to the Federal Government by Health Insurers — a consensus of the FASB Emerging Issues Task Force

ASU 2010-27, Other Expenses (Topic 720): Fees Paid to the Federal Government by Pharmaceutical Manufacturers — a consensus of the FASB Emerging Issues Task Force

ASU 2010-20, Receivables (Topic 310): Disclosures About the Credit Quality of Financing Receivables and the Allowance for Credit Losses

ASU 2009-13, Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force

**FASB Accounting Standards Codification (ASC) Topics**

ASC 205, Presentation of Financial Statements

ASC 210, Balance Sheet

ASC 220, Income Statement — Reporting Comprehensive Income

ASC 230, Statement of Cash Flows

ASC 235, Notes to Financial Statements

ASC 250, Accounting Changes and Error Corrections

ASC 260, Earnings per Share

ASC 280, Segment Reporting

ASC 320, Investments — Debt and Equity Securities

ASC 321, Investments — Equity Securities

ASC 323, Investments — Equity Method and Joint Ventures

ASC 325, Investments — Other

ASC 326, Financial Instruments — Credit Losses

ASC 330, Inventory

ASC 350, Intangibles — Goodwill and Other

ASC 360, Property, Plant, and Equipment

ASC 410, Asset Retirement and Environmental Obligations
Appendix A — Glossary of Standards and Other Literature

ASC 420, Exit or Disposal Cost Obligations
ASC 450, Contingencies
ASC 470, Debt
ASC 480, Distinguishing Liabilities From Equity
ASC 505, Equity
ASC 605, Revenue Recognition
ASC 606, Revenue From Contracts With Customers
ASC 610, Other Income
ASC 715, Compensation — Retirement Benefits
ASC 718, Compensation — Stock Compensation
ASC 720, Other Expenses
ASC 730, Research and Development
ASC 740, Income Taxes
ASC 805, Business Combinations
ASC 808, Collaborative Arrangements
ASC 810, Consolidation
ASC 815, Derivatives and Hedging
ASC 820, Fair Value Measurement
ASC 825, Financial Instruments
ASC 830, Foreign Currency Matters
ASC 840, Leases
ASC 842, Leases
ASC 845, Nonmonetary Transactions
ASC 915, Development Stage Entities
ASC 958, Not-for-Profit Entities
ASC 985, Software
Proposed FASB Accounting Standards Updates (Proposed ASUs)

Proposed ASU 2018-200, Leases (Topic 842): Targeted Improvements


FASB Proposed Accounting Standards Update 2017-280, Consolidation (Topic 812): Reorganization


Proposed ASU 2017-220, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

Proposed ASU 2017-210, Inventory (Topic 330): Disclosure Framework — Changes to the Disclosure Requirements for Inventory

Proposed ASU 2017-200, Debt (Topic 470): Simplifying the Classification of Debt in a Classified Balance Sheet (Current Versus Noncurrent)


Proposed ASU 2015-340, Government Assistance (Topic 832): Disclosures by Business Entities About Government Assistance

Proposed ASU 2015-310, Notes to Financial Statements (Topic 235): Assessing Whether Disclosures Are Material

Other FASB Proposal


FASB Statements (Pre-Codification Literature)

Statement No. 167, Amendments to FASB Interpretation No. 46(R)

Statement No. 160, Noncontrolling Interests in Consolidated Financial Statements — an amendment of ARB No. 51

Statement No. 141(R), Business Combinations

FASB Interpretations (Pre-Codification Literature)

FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109

FASB Interpretation No. 46 (revised December 2003), Consolidation of Variable Interest Entities
**FASB Concepts Statements**
No. 5, *Recognition and Measurement in Financial Statements of Business Enterprises*

No. 6, *Elements of Financial Statements*

**EITF Issues (Pre-Codification Literature)**
Issue 09-4, “Seller Accounting for Contingent Consideration”

Issue 08-1, “Revenue Arrangements With Multiple Deliverables”

Issue 04-5, “Determining Whether a General Partner, or the General Partners as a Group, Controls a Limited Partnership or Similar Entity When the Limited Partners Have Certain Rights”

Issue 01-9, “Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products)”

Issue 01-8, “Determining Whether an Arrangement Contains a Lease”

Issue 00-21, “Revenue Arrangements With Multiple Deliverables”

**PCAOB Auditing Standard**

**SEC C&DI Topic**
Non-GAAP Financial Measures

**SEC Interpretive Release**
33-10403, *Updates to Commission Guidance Regarding Accounting for Sales of Vaccines and Bioterror Countermeasures to the Federal Government for Placement Into the Pediatric Vaccine Stockpile or the Strategic National Stockpile*

**SEC Regulation G**
“Conditions for Use of Non-GAAP Financial Measures”

**SEC Regulation S-K**
Item 10(e), “General; Use of Non-GAAP Financial Measures in Commission Filings”

Item 103, “Business; Legal Proceedings.”

**SEC Regulation S-X**
Rule 3-05, “Financial Statements of Businesses Acquired or to Be Acquired”

Rule 3-09, “Separate Financial Statements of Subsidiaries Not Consolidated and 50 Percent or Less Owned Persons”

Rule 3-14, “Special Instructions for Real Estate Operations to Be Acquired”
Rule 4-08(g), “General Notes to Financial Statements; Summarized Financial Information of Subsidiaries Not Consolidated and 50 Percent or Less Owned Persons”

Rule 4-08(h), “General Notes to Financial Statements; Income Tax Expense”

**SEC Staff Accounting Bulletins (SABs)**

SAB Topic 1.M, “Financial Statements; Materiality”

SAB Topic 5.Y, “Miscellaneous Accounting; Accounting and Disclosures Relating to Loss Contingencies”

SAB Topic 11.A, “Miscellaneous Disclosure; Operating-Differential Subsidies”

SAB Topic 13, “Revenue Recognition”

SAB Topic 13.A.4, “Revenue Recognition; Selected Revenue Recognition Issues; Fixed or Determinable Sales Price”

SAB Topic 13.B, “Revenue Recognition; Disclosures”

SAB 116, “Staff Accounting Bulletin No. 116”

SAB 118, codified as SEC Staff Accounting Bulletin Topic 5.EE, “Miscellaneous Accounting; Income Tax Accounting Implications of the Tax Cuts and Jobs Act”

**Internal Revenue Code (IRC)**

IRC Section 78, “Gross Up for Deemed Paid Foreign Tax Credit”

IRC Section 163(j), “Interest; Limitation on Business Interest”

IRC Section 199, “Income Attributable to Domestic Production Activities”

IRC Section 383, “Special Limitations on Certain Excess Credits, Etc.”

IRC Section 787, “Termination of Private Foundation Status”

IRC Section 965, “Treatment of Deferred Foreign Income Upon Transition to Participation Exemption System of Taxation”

IRC Section 4191, “Medical Devices”

**International Standards**

IFRS 16, *Leases*

IFRS 15, *Revenue From Contracts With Customers*

IFRS 11, *Joint Arrangements*

IFRS 3, *Business Combinations*

IAS 20, *Accounting for Government Grants and Disclosure of Government Assistance*
## Appendix B — Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFS</td>
<td>available for sale</td>
</tr>
<tr>
<td>AICPA</td>
<td>American Institute of Certified Public Accountants</td>
</tr>
<tr>
<td>AMT</td>
<td>alternative minimum tax</td>
</tr>
<tr>
<td>AOCl</td>
<td>accumulated other comprehensive income</td>
</tr>
<tr>
<td>API</td>
<td>active pharmaceutical ingredient</td>
</tr>
<tr>
<td>APIC</td>
<td>additional paid-in capital</td>
</tr>
<tr>
<td>ASC</td>
<td>FASB Accounting Standards Codification</td>
</tr>
<tr>
<td>ASU</td>
<td>FASB Accounting Standards Update</td>
</tr>
<tr>
<td>BCF</td>
<td>beneficial conversion feature</td>
</tr>
<tr>
<td>BEAT</td>
<td>base erosion anti-abuse tax</td>
</tr>
<tr>
<td>BEMTA</td>
<td>base erosion minimum tax amount</td>
</tr>
<tr>
<td>BPD</td>
<td>branded prescription drug</td>
</tr>
<tr>
<td>BOLI</td>
<td>bank-owned life insurance</td>
</tr>
<tr>
<td>CAM</td>
<td>critical audit matter</td>
</tr>
<tr>
<td>C&amp;DI</td>
<td>SEC Compliance and Disclosure Interpretation</td>
</tr>
<tr>
<td>CECL</td>
<td>current expected credit loss</td>
</tr>
<tr>
<td>CFC</td>
<td>controlled foreign corporation</td>
</tr>
<tr>
<td>CODDM</td>
<td>chief operating decision maker</td>
</tr>
<tr>
<td>COLI</td>
<td>corporate-owned life insurance</td>
</tr>
<tr>
<td>CRO</td>
<td>contract research organization</td>
</tr>
<tr>
<td>CTA</td>
<td>cumulative translation adjustment</td>
</tr>
<tr>
<td>DCPs</td>
<td>disclosure controls and procedures</td>
</tr>
<tr>
<td>DTA</td>
<td>deferred tax asset</td>
</tr>
<tr>
<td>DTL</td>
<td>deferred tax liability</td>
</tr>
<tr>
<td>EBITDA</td>
<td>earnings before interest, taxes, depreciation, and amortization</td>
</tr>
<tr>
<td>EITF</td>
<td>FASB Emerging Issues Task Force</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E&amp;P</td>
<td>earnings and profits</td>
</tr>
<tr>
<td>EPS</td>
<td>earnings per share</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FAQ</td>
<td>frequently asked question</td>
</tr>
<tr>
<td>FASB</td>
<td>Financial Accounting Standards Board</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FDII</td>
<td>foreign derived intangible income</td>
</tr>
<tr>
<td>FIFO</td>
<td>first in, first out</td>
</tr>
<tr>
<td>FIN</td>
<td>FASB Interpretation Number (superseded)</td>
</tr>
<tr>
<td>FOB</td>
<td>free on board</td>
</tr>
<tr>
<td>GAAP</td>
<td>generally accepted accounting principles</td>
</tr>
<tr>
<td>GILT1</td>
<td>global intangible low-taxed income</td>
</tr>
<tr>
<td>GPO</td>
<td>group purchasing organization</td>
</tr>
<tr>
<td>IAS</td>
<td>International Accounting Standard</td>
</tr>
<tr>
<td>IASB</td>
<td>International Accounting Standards Board</td>
</tr>
<tr>
<td>IFRS</td>
<td>International Financial Reporting Standard</td>
</tr>
<tr>
<td>IIR</td>
<td>investigator-initiated research</td>
</tr>
<tr>
<td>IP</td>
<td>intellectual property</td>
</tr>
<tr>
<td>IPO</td>
<td>initial public offering</td>
</tr>
<tr>
<td>IPR&amp;D</td>
<td>in-process research and development</td>
</tr>
<tr>
<td>IRC</td>
<td>Internal Revenue Code</td>
</tr>
<tr>
<td>IRS</td>
<td>Internal Revenue Service</td>
</tr>
<tr>
<td>IT</td>
<td>information technology</td>
</tr>
<tr>
<td>LIFO</td>
<td>last in, first out</td>
</tr>
<tr>
<td>LLC</td>
<td>limited liability company</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>LP</td>
<td>limited partnership</td>
</tr>
<tr>
<td>M&amp;A</td>
<td>merger and acquisition</td>
</tr>
<tr>
<td>MD&amp;A</td>
<td>Management’s Discussion and Analysis</td>
</tr>
<tr>
<td>MDET</td>
<td>medical device excise tax</td>
</tr>
<tr>
<td>MSL</td>
<td>medical science liaison</td>
</tr>
<tr>
<td>NFP</td>
<td>not-for-profit entity</td>
</tr>
<tr>
<td>NOL</td>
<td>net operating loss</td>
</tr>
<tr>
<td>OCI</td>
<td>other comprehensive income</td>
</tr>
<tr>
<td>OEM</td>
<td>original equipment manufacturer</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Co-operation and Development</td>
</tr>
<tr>
<td>PBE</td>
<td>public business entity</td>
</tr>
<tr>
<td>PCAOB</td>
<td>Public Company Accounting Oversight Board</td>
</tr>
<tr>
<td>PCC</td>
<td>Private Company Council</td>
</tr>
<tr>
<td>PCD asset</td>
<td>purchased financial asset with credit deterioration</td>
</tr>
<tr>
<td>PRV</td>
<td>priority review voucher</td>
</tr>
<tr>
<td>PTRS</td>
<td>probability of technical and regulatory success</td>
</tr>
<tr>
<td>Q&amp;A</td>
<td>question and answer</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>research and development</td>
</tr>
<tr>
<td>R&amp;E</td>
<td>research and experimentation</td>
</tr>
<tr>
<td>REMS</td>
<td>risk evaluation and mitigation strategy</td>
</tr>
<tr>
<td>ROU</td>
<td>right-of-use</td>
</tr>
<tr>
<td>SAB</td>
<td>SEC Staff Accounting Bulletin</td>
</tr>
<tr>
<td>SEC</td>
<td>Securities and Exchange Commission</td>
</tr>
<tr>
<td>SFC</td>
<td>specified foreign corporation</td>
</tr>
<tr>
<td>SIFMA</td>
<td>Securities Industry and Financial Markets Association</td>
</tr>
<tr>
<td>T.D.</td>
<td>Treasury Decision</td>
</tr>
<tr>
<td>TRG</td>
<td>transition resource group</td>
</tr>
<tr>
<td>UTB</td>
<td>unrecognized tax benefit</td>
</tr>
<tr>
<td>VIE</td>
<td>variable interest entity</td>
</tr>
<tr>
<td>WAC</td>
<td>wholesaler acquisition cost</td>
</tr>
</tbody>
</table>
Contacts
If you have any questions about this publication, please contact the following Deloitte industry specialists:

Chris Cooper
U.S. Audit Leader — Life Sciences and Health Care
Deloitte & Touche LLP
+1 973 602 6623
ccooper@deloitte.com

Jeff Ellis
Life Sciences Industry Professional Practice Director
Deloitte & Touche LLP
+1 412 338 7204
jeellis@deloitte.com

Dennis Howell
Senior Consultation Partner, Accounting Services and
Life Sciences Deputv Industry Professional Practice
Director
Deloitte & Touche LLP
+1 203 761 3478
dhowell@deloitte.com

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.

Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

As used in this document, “Deloitte” means Deloitte & Touche LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Copyright © 2018 Deloitte Development LLC. All rights reserved.